Overview

Efficacy and Safety of DA-3002 in Short Children Borns SGA.

Status:
Completed
Trial end date:
2019-08-28
Target enrollment:
Participant gender:
Summary
A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin® in short children born small for gestational age.
Phase:
Phase 3
Details
Lead Sponsor:
Dong-A ST Co., Ltd.